BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med. 1995;123:161-167. [PMID: 7598296 DOI: 10.7326/0003-4819-123-3-199508010-00001] [Cited by in Crossref: 259] [Cited by in F6Publishing: 214] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Chuquilin M, Alghalith Y, Fernandez KH. Neurocutaneous disease. Journal of the American Academy of Dermatology 2016;74:197-212. [DOI: 10.1016/j.jaad.2015.04.060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
2 Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol 2017; 23(19): 3418-3426 [PMID: 28596678 DOI: 10.3748/wjg.v23.i19.3418] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
3 Rajagopalan M, Saraswat A, Godse K, Shankar DS, Kandhari S, Shenoi SD, Tahiliani S, Zawar VV. Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review. Indian J Dermatol 2017;62:7-17. [PMID: 28216719 DOI: 10.4103/0019-5154.198036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Hamilton JP, Laurin JM. Drug-Induced Cholestasis. In: Lindor KD, Talwalkar JA, editors. Cholestatic Liver Disease. Totowa: Humana Press; 2008. pp. 21-43. [DOI: 10.1007/978-1-59745-118-5_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
5 Mackinnon KL, Zuzel KA, David B. Hepatic inactivation of Leu-enkephalin. Regulatory Peptides 1996;67:85-92. [DOI: 10.1016/s0167-0115(96)00117-6] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
6 Andoh T, Maki T, Li S, Uta D. β2-Microglobulin elicits itch-related responses in mice through the direct activation of primary afferent neurons expressing transient receptor potential vanilloid 1. Eur J Pharmacol 2017;810:134-40. [PMID: 28687195 DOI: 10.1016/j.ejphar.2017.07.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
7 Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Review of Gastroenterology & Hepatology 2014;4:473-88. [DOI: 10.1586/egh.10.33] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
8 Li S, Andoh T, Zhang Q, Uta D, Kuraishi Y. β2-Microglobulin, interleukin-31, and arachidonic acid metabolites (leukotriene B4 and thromboxane A2) are involved in chronic renal failure-associated itch-associated responses in mice. European Journal of Pharmacology 2019;847:19-25. [DOI: 10.1016/j.ejphar.2019.01.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Feng J, Sethi A, Reyes-Múgica M, Antaya R. Life-threatening blood loss from scratching provoked by pruritus in the bulky perineal nevocytoma variant of giant congenital melanocytic nevus in a child. J Am Acad Dermatol 2005;53:S139-42. [PMID: 16021164 DOI: 10.1016/j.jaad.2004.12.040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S, Bigliardi-qi M. Treatment of pruritus with topically applied opiate receptor antagonist. Journal of the American Academy of Dermatology 2007;56:979-88. [DOI: 10.1016/j.jaad.2007.01.007] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
11 O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005;21:1041-5. [PMID: 15813840 DOI: 10.1111/j.1365-2036.2005.02430.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
12 Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2016;11:CD008320. [PMID: 27849111 DOI: 10.1002/14651858.CD008320.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
13 Bergasa NV. Lysophosphatidic acid and atotaxin in patients with cholestasis and pruritus: Fine biology, anticipated discernment. Annals of Hepatology 2010;9:475-9. [DOI: 10.1016/s1665-2681(19)31629-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
15 van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, Schalm SW. The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res 2004;13:1469-81. [PMID: 15503842 DOI: 10.1023/B:QURE.0000040797.17449.c0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
16 Bassari R, Koea JB. Jaundice associated pruritis: A review of pathophysiology and treatment. World J Gastroenterol 2015; 21(5): 1404-1413 [PMID: 25663760 DOI: 10.3748/wjg.v21.i5.1404] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
17 Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, Mcgee M. Pilot Study of Bright-Light Therapy Reflected Toward the Eyes for the Pruritus of Chronic Liver Disease. American Journal of Gastroenterology 2001;96:1563-70. [DOI: 10.1111/j.1572-0241.2001.03778.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
18 Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, Iaina A. Randomised crossover trial of naltrexone in uraemic pruritus. The Lancet 1996;348:1552-4. [DOI: 10.1016/s0140-6736(96)04176-1] [Cited by in Crossref: 189] [Cited by in F6Publishing: 32] [Article Influence: 7.3] [Reference Citation Analysis]
19 Böttcher B, Wildt L. Treatment of refractory vulvovaginal pruritus with naltrexone, a specific opiate antagonist. European Journal of Obstetrics & Gynecology and Reproductive Biology 2014;174:115-6. [DOI: 10.1016/j.ejogrb.2013.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Yosipovitch G. Pruritus. Current Problems in Dermatology 2003;15:143-64. [DOI: 10.1016/s1040-0486(03)00017-6] [Cited by in Crossref: 14] [Article Influence: 0.7] [Reference Citation Analysis]
21 Bergasa NV, Jones EA. THE PRURITUS OF CHOLESTASIS. Clinics in Liver Disease 1998;2:391-405. [DOI: 10.1016/s1089-3261(05)70014-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Lotsch J, Skarke C, Tegeder I, Geisslinger G. Drug Interactions with Patient-Controlled Analgesia: . Clinical Pharmacokinetics 2002;41:31-57. [DOI: 10.2165/00003088-200241010-00004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
23 Pauli-magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T. Naltrexone Does Not Relieve Uremic Pruritus: Results of a Randomized, Double-Blind, Placebo-Controlled Crossover Study. JASN 2000;11:514-9. [DOI: 10.1681/asn.v113514] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
24 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. The American Journal of Medicine 2017;130:744.e1-7. [DOI: 10.1016/j.amjmed.2017.01.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
25 Schäkel K, Döbel T, Bosselmann I. Future treatment options for atopic dermatitis – Small molecules and beyond. Journal of Dermatological Science 2014;73:91-100. [DOI: 10.1016/j.jdermsci.2013.11.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
26 Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology. 1999;29:1003-1006. [PMID: 10094938 DOI: 10.1002/hep.510290450] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 5.1] [Reference Citation Analysis]
27 Davis M. Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 2007;46:825-50. [PMID: 17854233 DOI: 10.2165/00003088-200746100-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
28 Neff GW, O'Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, Rodriguez MJ, Chase V, Jeffers L, Schiff E. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97:2117-2119. [PMID: 12190187 DOI: 10.1111/j.1572-0241.2002.05852.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
29 Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review. BMJ Support Palliat Care 2021;11:217-25. [PMID: 33692114 DOI: 10.1136/bmjspcare-2020-002801] [Reference Citation Analysis]
30 Andoh T, Yoshida T, Lee J, Kuraishi Y. Cathepsin E induces itch-related response through the production of endothelin-1 in mice. European Journal of Pharmacology 2012;686:16-21. [DOI: 10.1016/j.ejphar.2012.04.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
31 Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, Rodés J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004;99:1105-1110. [PMID: 15180733 DOI: 10.1111/j.1572-0241.2004.30204.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
32 Kiani S, Ebrahimkhani MR, Shariftabrizi A, Doratotaj B, Payabvash S, Riazi K, Dehghani M, Honar H, Karoon A, Amanlou M. Opioid system blockade decreases collagenase activity and improves liver injury in a rat model of cholestasis. J Gastroenterol Hepatol. 2007;22:406-413. [PMID: 17295775 DOI: 10.1111/j.1440-1746.2006.04260.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
33 Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J. Pruritus: Progress toward Pathogenesis and Treatment. Biomed Res Int 2018;2018:9625936. [PMID: 29850592 DOI: 10.1155/2018/9625936] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
34 Huesmann M, Huesmann T, Osada N, Phan NQ, Kremer AE, Ständer S. Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response. J Dtsch Dermatol Ges. 2013;11:158-168. [PMID: 23190476 DOI: 10.1111/j.1610-0387.2012.08028.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
35 Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. Journal of Gastroenterology and Hepatology 2002;17:938-48. [DOI: 10.1046/j.1440-1746.2002.02717.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
36 Bergasa N, Liau S, Homel P, Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis: Met-enkephalin in PBC livers. Liver 2002;22:107-13. [DOI: 10.1034/j.1600-0676.2002.01458.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
37 Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. Journal of the American Academy of Dermatology 2006;54:527-31. [DOI: 10.1016/j.jaad.2005.12.010] [Cited by in Crossref: 120] [Cited by in F6Publishing: 83] [Article Influence: 7.5] [Reference Citation Analysis]
38 Świerczyńska K, Białynicki-Birula R, Szepietowski JC. Chronic Intractable Pruritus in Chronic Kidney Disease Patients: Prevalence, Impact, and Management Challenges - A Narrative Review. Ther Clin Risk Manag 2021;17:1267-82. [PMID: 34876816 DOI: 10.2147/TCRM.S310550] [Reference Citation Analysis]
39 Bergasa NV. Hypothesis: Taste Disorders in Patients With Liver Disease May Be Mediated in the Brain: Potential Mechanisms for a Central Phenomenon. American Journal of Gastroenterology 1998;93:1209-10. [DOI: 10.1111/j.1572-0241.1998.00396.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
40 Mettang T, Streit M, Weisshaar E. Pruritus bei inneren Erkrankungen. Hautarzt 2006;57:395-402. [DOI: 10.1007/s00105-006-1124-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
42 Jones EA. Pruritus and fatigue associated with liver disease: is there a role for ondansetron? Expert Opinion on Pharmacotherapy 2008;9:645-51. [DOI: 10.1517/14656566.9.4.645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
43 Welz-kubiak K, Reszke R, Szepietowski JC. Pruritus as a sign of systemic disease. Clinics in Dermatology 2019;37:644-56. [DOI: 10.1016/j.clindermatol.2019.07.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
44 Sanchez W, Talwalkar JA. Palliative care for patients with end-stage liver disease ineligible for liver transplantation. Gastroenterol Clin North Am 2006;35:201-19. [PMID: 16530121 DOI: 10.1016/j.gtc.2005.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
45 Bentley KW. β-Phenylethylamines and the isoquinoline alkaloids. Nat Prod Rep 1997;14:387. [DOI: 10.1039/np9971400387] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
46 McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-6. [PMID: 12891561 DOI: 10.1016/s0016-5085(03)00879-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
47 Molenaar HAJ, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998;36:220-4. [DOI: 10.1007/bf02510746] [Cited by in Crossref: 28] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
48 Boyella VD, Nicastri AD, Bergasa NV. Human hepatic met-enkephalin and delta opioid receptor-1 immunoreactivities in viral and autoimmune hepatitis. Annals of Hepatology 2008;7:221-5. [DOI: 10.1016/s1665-2681(19)31851-4] [Cited by in Crossref: 13] [Article Influence: 0.9] [Reference Citation Analysis]
49 LaMotte RH, Shimada SG, Sikand P. Mouse models of acute, chemical itch and pain in humans. Exp Dermatol 2011;20:778-82. [PMID: 21929688 DOI: 10.1111/j.1600-0625.2011.01367.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
50 Terán A, Fábrega E, Pons-Romero F. [Pruritus associated with cholestasis]. Gastroenterol Hepatol 2010;33:313-22. [PMID: 19836105 DOI: 10.1016/j.gastrohep.2009.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Andoh T, Kuwazono T, Lee JB, Kuraishi Y. Gastrin-releasing peptide induces itch-related responses through mast cell degranulation in mice. Peptides 2011;32:2098-103. [PMID: 21933692 DOI: 10.1016/j.peptides.2011.09.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
52 Moezi L, Dehpour AR. Cardiovascular abnormalities in obstructive cholestasis: the possible mechanisms. Liver Int 2013;33:7-15. [DOI: 10.1111/j.1478-3231.2012.02803.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
53 Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis. 2000;32:621-625. [PMID: 11142563 DOI: 10.1016/s1590-8658(00)80847-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
54 Liang J, Xiao G, Ji W. Capsaicin induces reflex scratching in inflamed skin. Pharmacology 2011;88:82-7. [PMID: 21846999 DOI: 10.1159/000330094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
55 Bergasa NV, Vergalla J, Swain MG, Jones EA. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996;16:298-302. [DOI: 10.1111/j.1600-0676.1996.tb00749.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
56 Terra SG, Tsunoda SM. Opioid antagonists in the treatment of pruritus from cholestatic liver disease. Ann Pharmacother 1998;32:1228-30. [PMID: 9825091 DOI: 10.1345/aph.18115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
57 Etter L, Myers SA. Pruritus in systemic disease: mechanisms and management. Dermatologic Clinics 2002;20:459-72. [DOI: 10.1016/s0733-8635(02)00011-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
58 Huang CS, Lichtenstein DR. Treatment of Biliary Problems in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2005;8:117-26. [PMID: 15769433 DOI: 10.1007/s11938-005-0004-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Shirazian S, Aina O, Park Y, Chowdhury N, Leger K, Hou L, Miyawaki N, Mathur VS. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis 2017;10:11-26. [PMID: 28176969 DOI: 10.2147/IJNRD.S108045] [Cited by in Crossref: 32] [Cited by in F6Publishing: 13] [Article Influence: 6.4] [Reference Citation Analysis]
60 Nakasone T, Sato T, Matsushima Y, Inoue T, Kamei C. Characteristics of scratching behavior in ADJM mice (atopic dermatitis from Japanese mice). Immunopharmacol Immunotoxicol 2015;37:202-6. [PMID: 25578901 DOI: 10.3109/08923973.2014.1001903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
61 Greaves MW. Itch in systemic disease: therapeutic options: Itch in systemic disease. Dermatologic Therapy 2005;18:323-7. [DOI: 10.1111/j.1529-8019.2005.00036.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
62 Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006;44:1317-1323. [PMID: 17058231 DOI: 10.1002/hep.21370] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
63 Lee J, Shin JU, Noh S, Park CO, Lee KH. Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus. Ann Dermatol 2016;28:159-63. [PMID: 27081261 DOI: 10.5021/ad.2016.28.2.159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
64 Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Letters to the Editors 2012;35:696-704. [DOI: 10.1111/j.1365-2036.2012.04994.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
65 Liu W, Yang B, Ji JW, Yang H, Song HH, Qiu HB, Song JC. The effect of obstructive jaundice on the sensitivity of intravenous anesthetic of remimazolam: study protocol for a controlled multicenter trial. Trials 2022;23:23. [PMID: 34998423 DOI: 10.1186/s13063-021-05987-y] [Reference Citation Analysis]
66 Lasalle L, Rachelska G, Nedelec B. Naltrexone for the management of post-burn pruritus: A preliminary report. Burns 2008;34:797-802. [DOI: 10.1016/j.burns.2007.10.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
67 Kiani S, Valizadeh B, Hormazdi B, Samadi H, Najafi T, Samini M, Dehpour AR. Alteration in male reproductive system in experimental cholestasis: Roles for opioids and nitric oxide overproduction. European Journal of Pharmacology 2009;615:246-51. [DOI: 10.1016/j.ejphar.2009.04.049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
68 Zellos A, Roy A, Schwarz KB. Use of oral naltrexone for severe pruritus due to cholestatic liver disease in children. J Pediatr Gastroenterol Nutr 2010;51:787-9. [PMID: 20948447 DOI: 10.1097/MPG.0b013e3181eb5ac0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
69 Kosmadakis G, Zerefos N. Uremic Pruritus. Int J Artif Organs 2006;29:938-43. [DOI: 10.1177/039139880602901003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Patel AD, Katz K, Gordon KB. Cutaneous Manifestations of Chronic Liver Disease. Clin Liver Dis 2020;24:351-60. [PMID: 32620276 DOI: 10.1016/j.cld.2020.04.003] [Reference Citation Analysis]
71 Mcgill JM, Kwiatkowski AP. Cholestatic Liver Diseases in Adults. American Journal of Gastroenterology 1998;93:684-91. [DOI: 10.1111/j.1572-0241.1998.206_a.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45:666-674. [PMID: 17326161 DOI: 10.1002/hep.21553] [Cited by in Crossref: 192] [Cited by in F6Publishing: 128] [Article Influence: 12.8] [Reference Citation Analysis]
73 Chia SC, Bergasa NV, Kleiner DE, Goodman Z, Hoofnagle JH, Di Bisceglie AM. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci. 1998;43:2177-2183. [PMID: 9790451 DOI: 10.1023/a:1026646017851] [Cited by in Crossref: 47] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
74 Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. J Cell Mol Med 2001;5:98-115. [PMID: 12067457 DOI: 10.1111/j.1582-4934.2001.tb00144.x] [Reference Citation Analysis]
75 Jones EA, Bergasa NV. Why do cholestatic patients itch? Gut 1996;38:644-5. [PMID: 8707105 DOI: 10.1136/gut.38.5.644] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
76 Grundmann SA, Ständer S. Evaluation of chronic pruritus in older patients. Aging Health 2010;6:53-66. [DOI: 10.2217/ahe.09.84] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
77 Dehpour AR, Sadeghipour HR, Nowroozi A, Akbarloo N. The effect of the serotonergic system on opioid withdrawal-like syndrome in a mouse model of cholestasis. Hum Psychopharmacol 2000;15:423-8. [PMID: 12404304 DOI: 10.1002/1099-1077(200008)15:6<423::AID-HUP214>3.0.CO;2-V] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
78 Bergasa NV, Jones EA. Assessment of the Visual Analogue Score in the Evaluation of the Pruritus of Cholestasis. J Clin Transl Hepatol 2017;5:203-7. [PMID: 28936401 DOI: 10.14218/JCTH.2017.00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Kunzmann S, Kullak-ublick GA, Greiner A, Jeschke R, Hebestreit H. Effective Opiate-Receptor Antagonist Therapy of Cholestatic Pruritus Induced by an Oral Contraceptive: . Journal of Pediatric Gastroenterology and Nutrition 2005;40:596-9. [DOI: 10.1097/01.mpg.0000148775.64966.96] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Homayoun H, Sayyah M, Dehpour AR. The additive effect of opioids and nitric oxide in increasing pentylenetetrazole-induced seizure threshold in cholestatic mice. J Gastroenterol Hepatol 2002;17:96-101. [DOI: 10.1046/j.1440-1746.2002.02658.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
81 Meixiong J, Vasavda C, Snyder SH, Dong X. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus. Proc Natl Acad Sci U S A. 2019;116:10525-10530. [PMID: 31068464 DOI: 10.1073/pnas.1903316116] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
82 Zeidler C, Ständer S. [Therapy of prurigo nodularis]. Hautarzt. 2014;65:709-713. [PMID: 25113330 DOI: 10.1007/s00105-014-2757-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
83 Gossard AA, Lindor KD. Current and promising therapy for primary biliary cholangitis. Expert Opinion on Pharmacotherapy 2019;20:1161-7. [DOI: 10.1080/14656566.2019.1601701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
84 Angulo P, Lindor KD. PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS. Clinics in Liver Disease 1999;3:529-70. [DOI: 10.1016/s1089-3261(05)70084-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
85 Verduzco HA, Shirazian S. CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management. Kidney Int Rep 2020;5:1387-402. [PMID: 32954065 DOI: 10.1016/j.ekir.2020.04.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
86 Joshi GG, Thakur BS, Sircar S, Namdeo A, Jain AK. Role of intravenous naloxone in severe pruritus of acute cholestasis. Indian J Gastroenterol 2009;28:180-2. [DOI: 10.1007/s12664-009-0070-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
87 Mccain JD, Chascsa DM, Lindor KD. Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. Expert Opinion on Orphan Drugs 2021;9:53-66. [DOI: 10.1080/21678707.2021.1898370] [Reference Citation Analysis]
88 Floreani A, Sun Y, Zou ZS, Li B, Cazzagon N, Bowlus CL, Gershwin ME. Proposed therapies in primary biliary cholangitis. Expert Rev Gastroenterol Hepatol 2016;10:371-82. [PMID: 26577047 DOI: 10.1586/17474124.2016.1121810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
89 Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol. 2010;53:307-312. [PMID: 20580987 DOI: 10.1016/j.jhep.2010.02.031] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
90 Pereira MP, Ständer S. Therapy for pruritus in the elderly: a review of treatment developments. Expert Opinion on Pharmacotherapy 2018;19:443-50. [DOI: 10.1080/14656566.2018.1444752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
91 Reszke R, Szepietowski JC. Can we use psychoactive drugs to treat pruritus? Exp Dermatol 2019;28:1422-31. [PMID: 31087719 DOI: 10.1111/exd.13959] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
92 Yatsuzuka R, Inoue T, Jiang S, Nakano Y, Kamei C. Development of new atopic dermatitis models characterized by not only itching but also inflammatory skin in mice. European Journal of Pharmacology 2007;565:225-31. [DOI: 10.1016/j.ejphar.2007.02.062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
93 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:28:2:147] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
94 Chen J, Deng W, Wang J, Shao Y, Ou M, Ding M. Primary bile acids as potential biomarkers for the clinical grading of intrahepatic cholestasis of pregnancy. Int J Gynaecol Obstet 2013;122:5-8. [PMID: 23562588 DOI: 10.1016/j.ijgo.2013.02.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
95 Tandon P, Rowe BH, Vandermeer B, Bain VG. The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. Am J Gastroenterology 2007;102:1528-36. [DOI: 10.1111/j.1572-0241.2007.01200.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
96 Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273-1291. [PMID: 21501198 DOI: 10.1111/j.1365-2036.2011.04658.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
97 Reszke R, Krajewski P, Szepietowski JC. Emerging Therapeutic Options for Chronic Pruritus. Am J Clin Dermatol 2020;21:601-18. [PMID: 32607945 DOI: 10.1007/s40257-020-00534-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008-1018, 1018.e1. [PMID: 20546739 DOI: 10.1053/j.gastro.2010.05.009] [Cited by in Crossref: 252] [Cited by in F6Publishing: 213] [Article Influence: 21.0] [Reference Citation Analysis]
99 Ueda Y, Inoue T, Rahman MA, Yatsuzuka R, Jiang S, Kamei C. A new chronic itch model accompanied by skin lesions in hairless mice. Int Immunopharmacol 2006;6:1609-15. [PMID: 16919833 DOI: 10.1016/j.intimp.2006.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
100 Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-1013. [PMID: 10733559 DOI: 10.1053/he.2000.5984] [Cited by in Crossref: 290] [Cited by in F6Publishing: 249] [Article Influence: 13.2] [Reference Citation Analysis]
101 Trivella J, Levy C. Safety considerations for the management of cholestatic itch. Expert Opin Drug Saf 2021;20:915-24. [PMID: 33836644 DOI: 10.1080/14740338.2021.1915984] [Reference Citation Analysis]
102 Yamaguchi T, Nagasawa T, Satoh M, Kuraishi Y. Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice. Neuroscience Research 1999;35:77-83. [DOI: 10.1016/s0168-0102(99)00070-x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
103 Shawcross DL, Jalan R. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy. Gastroenterology 2001;121:743-4. [PMID: 11547785 DOI: 10.1053/gast.2001.27714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
104 Mullally BA, Hansen WF. Intrahepatic cholestasis of pregnancy: review of the literature. Obstet Gynecol Surv. 2002;57:47-52. [PMID: 11773831 DOI: 10.1097/00006254-200201000-00023] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
105 Jones EA. Personal view: a potential novel treatment for fatigue complicating chronic liver disease - how should its efficacy be evaluated? Aliment Pharmacol Ther 2006;23:1113-6. [DOI: 10.1111/j.1365-2036.2006.02862.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
106 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
107 Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sciences 2003;73:2741-7. [DOI: 10.1016/s0024-3205(03)00668-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
108 Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones E. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. Journal of the American Academy of Dermatology 1999;41:431-4. [DOI: 10.1016/s0190-9622(99)70117-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 12] [Article Influence: 5.1] [Reference Citation Analysis]
109 Nasehi M, Piri M, Abbolhasani K, Zarrindast MR. Involvement of opioidergic and nitrergic systems in memory acquisition and exploratory behaviors in cholestatic mice. Behav Pharmacol 2013;24:180-94. [PMID: 23604167 DOI: 10.1097/FBP.0b013e3283618aab] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Janas RM, Socha J, Warnawin K, Rujner J. Further studies on aminopeptidase-M in blood in children with cholestatic liver diseases and viral hepatitis. Dig Dis Sci 1999;44:170-6. [PMID: 9952239 DOI: 10.1023/a:1026626822298] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
111 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
112 Goodman A, Le bourdonnec B, Dolle R. Mu Opioid Receptor Antagonists: Recent Developments. ChemMedChem 2007;2:1552-70. [DOI: 10.1002/cmdc.200700143] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
113 Bergasa NV, Zhou J, Ravi J, Shi Q. The opioid peptide analog d-Ala2-Met-enkephalinamide decreases bile flow by a central mechanism☆. Peptides 1999;20:979-86. [DOI: 10.1016/s0196-9781(99)00091-1] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
114 Yaster M, Nichols DG. Pain management in the critically ill child. Indian J Pediatr 2001;68:749-69. [PMID: 11563253 DOI: 10.1007/BF02752416] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
115 Kumar N, Garg N, Bailey A. Opiate receptor antagonists for treatment of severe pruritus associated with advanced cholestatic liver disease. J Palliat Med. 2013;16:122-123. [PMID: 23391399 DOI: 10.1089/jpm.2012.0452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
116 Montagnese S, Nsemi LM, Cazzagon N, Facchini S, Costa L, Bergasa NV, Amodio P, Floreani A. Sleep-Wake profiles in patients with primary biliary cirrhosis. Liver Int 2013;33:203-9. [DOI: 10.1111/liv.12026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
117 Katz SK, Gordon KB, Roenigk HH. The cutaneous manifestations of gastrointestinal disease. Prim Care 1996;23:455-76. [PMID: 8888338 DOI: 10.1016/s0095-4543(05)70341-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
118 Terzioğlu B, Aypak C, Yananlı HR, Küçükibrahimoğlu E, Yurdaydın C, Gören MZ. 5-hydroxytryptamine release in the anterior hypothalamic and the hippocampal areas of cholestatic rats. Life Sciences 2006;78:1078-83. [DOI: 10.1016/j.lfs.2005.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
119 Andoh T, Saito A, Kuraishi Y. Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin. J Invest Dermatol 2009;129:2854-60. [PMID: 19657356 DOI: 10.1038/jid.2009.155] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
120 Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 2003;38 Suppl 1:S24-S37. [PMID: 12591184 DOI: 10.1016/s0168-8278(03)00006-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
121 Agrawal S, O'Connor R, Aoun E, Babich M. Intense pruritus in Epstein-Barr virus (EBV) hepatitis treated with naloxone drip. BMJ Case Rep 2015;2015:bcr2014207037. [PMID: 25628319 DOI: 10.1136/bcr-2014-207037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
122 Brune A, Metze D, Luger TA, Ständer S. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt 2004;55:1130-6. [PMID: 15517116 DOI: 10.1007/s00105-004-0802-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
123 Shafaroodi H, Ghasemi M, Dehpour AR. Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: Interaction between opioid and cannabinoid systems. Journal of Gastroenterology and Hepatology 2008;23:e251-7. [DOI: 10.1111/j.1440-1746.2007.05101.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
124 Dehpour AR, Samini M, Rastegar H, Ardeshiri AJ, Roushanzamir F, Jorjani M, Ahmadiani A. Effect of NMDA receptor antagonist on naloxone-precipitated withdrawal signs in cholestatic mice. Hum Psychopharmacol Clin Exp 2000;15:213-8. [DOI: 10.1002/(sici)1099-1077(200004)15:3<213::aid-hup159>3.0.co;2-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Greaves MW. Pruritus. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-18. [DOI: 10.1002/9781444317633.ch21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview: Pruritus in atopic dermatitis. Experimental Dermatology 2002;11:12-24. [DOI: 10.1034/j.1600-0625.2002.110102.x] [Cited by in Crossref: 155] [Cited by in F6Publishing: 132] [Article Influence: 7.8] [Reference Citation Analysis]
127 Hohl CM, Wong JK, Harlos MS. Methylnaltrexone to Palliate Pruritus in Terminal Hepatic Disease. J Palliat Care 2015;31:124-6. [PMID: 26201215 DOI: 10.1177/082585971503100209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
128 Krok KL, Munoz SJ. Management of autoimmune and cholestatic liver disorders. Clin Liver Dis 2009;13:295-316. [PMID: 19442920 DOI: 10.1016/j.cld.2009.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
129 Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150-1158. [PMID: 22413872 DOI: 10.1111/j.1440-1746.2012.07109.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
130 Song JC, Sun YM, Zhang MZ, Yang LQ, Tao TZ, Yu WF. The Etomidate Requirement Is Decreased in Patients with Obstructive Jaundice. Anesthesia & Analgesia 2011;113:1028-32. [DOI: 10.1213/ane.0b013e31822dac4a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
131 Lee YM, Kaplan MM. Management of primary sclerosing cholangitis. Am J Gastroenterol. 2002;97:528-534. [PMID: 11922543 DOI: 10.1111/j.1572-0241.2002.05585.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
132 Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, Joannidis M. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004;10:107-14. [DOI: 10.1002/lt.20001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
133 Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008; 14(21): 3338-3349 [PMID: 18528931 DOI: 10.3748/wjg.14.3338] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
134 Bergasa NV. The pruritus of cholestasis. Semin Dermatol 1995;14:302-12. [PMID: 8679436 DOI: 10.1016/s1085-5629(05)80052-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
135 Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, Nagai H. Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. European Journal of Pharmacology 2002;448:175-83. [DOI: 10.1016/s0014-2999(02)01933-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
136 Zakrzewska-pniewska B, Jędras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Neurophysiologie Clinique/Clinical Neurophysiology 2001;31:181-93. [DOI: 10.1016/s0987-7053(01)00257-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
137 Kremer AE. What are new treatment concepts in systemic itch? Exp Dermatol 2019;28:1485-92. [DOI: 10.1111/exd.14024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
138 Miyamoto T, Nojima H, Shinkado T, Nakahashi T, Kuraishi Y. Itch-associated response induced by experimental dry skin in mice. Jpn J Pharmacol 2002;88:285-92. [PMID: 11949883 DOI: 10.1254/jjp.88.285] [Cited by in Crossref: 124] [Cited by in F6Publishing: 109] [Article Influence: 6.2] [Reference Citation Analysis]
139 Gossard AA, Talwalkar JA. Cholestatic liver disease. Med Clin North Am 2014;98:73-85. [PMID: 24266915 DOI: 10.1016/j.mcna.2013.09.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
140 Jones EA. Fatigue complicating chronic liver disease. Metab Brain Dis. 2004;19:421-429. [PMID: 15554432 DOI: 10.1023/b:mebr.0000043986.70972.3b] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
141 Lonsdale-eccles A, Carmichael AJ. Treatment of Pruritus Associated with Systemic Disorders in the Elderly: A Review of the Role of New Therapies. Drugs & Aging 2003;20:197-208. [DOI: 10.2165/00002512-200320030-00004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
142 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
143 Gotoh Y, Andoh T, Kuraishi Y. Noradrenergic regulation of itch transmission in the spinal cord mediated by α-adrenoceptors. Neuropharmacology 2011;61:825-31. [DOI: 10.1016/j.neuropharm.2011.05.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
144 Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr Treat Options Gastro 2003;6:493-8. [DOI: 10.1007/s11938-003-0051-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
145 Bergasa NV. Medical palliation of the jaundiced patient with pruritus. Gastroenterol Clin North Am. 2006;35:113-123. [PMID: 16530114 DOI: 10.1016/j.gtc.2005.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
146 Yosipovitch G, David M. The diagnostic and therapeutic approach to idiopathic generalized pruritus. International Journal of Dermatology 1999;38:881-7. [DOI: 10.1046/j.1365-4362.1999.00798.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
147 Choi YS, Billings J. Opioid Antagonists. Journal of Pain and Symptom Management 2002;24:71-90. [DOI: 10.1016/s0885-3924(02)00424-4] [Cited by in Crossref: 105] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
148 Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 2008;30:490-6. [PMID: 18641540 DOI: 10.1097/FTD.0b013e3181816214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
149 Silveira MG, Lindor KD. Investigational drugs in phase II clinical trials for primary biliary cholangitis. Expert Opinion on Investigational Drugs 2017;26:1115-21. [DOI: 10.1080/13543784.2017.1371135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Chiu Y, Chen H, Chuang Y, Hsu S, Lai C, Pai M, Yang S, Peng Y. Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrology Dialysis Transplantation 2008;23:3685-9. [DOI: 10.1093/ndt/gfn303] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
151 Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:643-655. [PMID: 10976020 DOI: 10.1053/bega.2000.0109] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.0] [Reference Citation Analysis]
152 Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy 2010;65:805-21. [PMID: 20384615 DOI: 10.1111/j.1398-9995.2010.01995.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
153 Lewis JH, Zimmerman HJ. DRUG- AND CHEMICAL-INDUCED CHOLESTASIS. Clinics in Liver Disease 1999;3:433-64. [DOI: 10.1016/s1089-3261(05)70079-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
154 Xie ZY, Luo ZJ, Zhang JX. Progress in diagnosis and treatment of cholestasis. Shijie Huaren Xiaohua Zazhi 2007; 15(35): 3669-3673 [DOI: 10.11569/wcjd.v15.i35.3669] [Reference Citation Analysis]
155 Neuberger J, Jones EA. Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy. Eur J Gastroenterol Hepatol. 2001;13:1393-1394. [PMID: 11692070 DOI: 10.1097/00042737-200111000-00022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
156 Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology. 1998;27:679-684. [PMID: 9500694 DOI: 10.1002/hep.510270307] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 5.3] [Reference Citation Analysis]
157 Ng VL, Ryckman FC, Porta G, Miura IK, de Carvalho E, Servidoni MF, Bezerra JA, Balistreri WF. Long-term Outcome After Partial External Biliary Diversion for Intractable Pruritus in Patients With Intrahepatic Cholestasis: . Journal of Pediatric Gastroenterology and Nutrition 2000;30:152-6. [DOI: 10.1097/00005176-200002000-00011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 3.0] [Reference Citation Analysis]
158 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
159 Bellmann R, Feistritzer C, Zoller H, Graziadei IW, Schwaighofer H, Propst A, Wiedermann CJ, Joannidis M. Treatment of Intractable Pruritus in Drug Induced Cholestasis with Albumin Dialysis: A Report of Two Cases: . ASAIO Journal 2004;50:387-91. [DOI: 10.1097/01.mat.0000132552.58214.00] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
160 Pusl T, Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol. 2005;28:147-157. [PMID: 15879620 DOI: 10.1385/criai:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol. 2011;165:5-17. [PMID: 21219293 DOI: 10.1111/j.1365-2133.2011.10217.x.] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
162 Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117:1621-6. [PMID: 11886531 DOI: 10.1046/j.0022-202x.2001.01585.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 76] [Article Influence: 5.1] [Reference Citation Analysis]
163 Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet. 2003;362:53-61. [PMID: 12853201 DOI: 10.1016/s0140-6736(03)13808-1] [Cited by in Crossref: 230] [Cited by in F6Publishing: 61] [Article Influence: 12.1] [Reference Citation Analysis]
164 Barnett V, Twycross R, Mihalyo M, Wilcock A. Opioid Antagonists. Journal of Pain and Symptom Management 2014;47:341-52. [DOI: 10.1016/j.jpainsymman.2013.12.223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
165 Bergasa NV. An approach to the management of the pruritus of cholestasis. Clinics in Liver Disease 2004;8:55-66. [DOI: 10.1016/s1089-3261(03)00128-4] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
166 Gossard AA. Care of the cholestatic patient. Clin Liver Dis 2013;17:331-44. [PMID: 23540506 DOI: 10.1016/j.cld.2012.11.005] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
167 Xander C, Meerpohl JJ, Galandi D, Buroh S, Schwarzer G, Antes G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2013;:CD008320. [PMID: 23749733 DOI: 10.1002/14651858.CD008320.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
168 Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69:394-419. [PMID: 30070375 DOI: 10.1002/hep.30145] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]
169 Bigliardi P, Bigliardi-qi M. Commentary 4. Exp Dermatol 2005;14:236-7. [DOI: 10.1111/j.0906-6705.2005.00321j.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
170 Bergasa NV. The pruritus of cholestasis: facts. Hepatology 2015;61:2114. [PMID: 25345776 DOI: 10.1002/hep.27582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
171 Kuraishi Y, Yamaguchi T, Miyamoto T. Itch-scratch responses induced by opioids through central Mu opioid receptors in mice. J Biomed Sci 2000;7:248-52. [DOI: 10.1007/bf02255473] [Cited by in Crossref: 46] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
172 Gaskari SA, Mani AR, Ejtemaei-Mehr S, Namiranian K, Homayoun H, Ahmadi H, Dehpour AR. Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis? Fundam Clin Pharmacol 2002;16:273-9. [PMID: 12570015 DOI: 10.1046/j.1472-8206.2002.00089.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
173 Greaves MW. Pathogenesis and treatment of pruritus. Curr Allergy Asthma Rep 2010;10:236-42. [PMID: 20428977 DOI: 10.1007/s11882-010-0117-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
174 Bergasa NV. Studying pruritus in the 21st century. Clinical Gastroenterology and Hepatology 2003;1:249-51. [DOI: 10.1016/s1542-3565(03)00140-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Kambia K, Bah S, Dine T, Azar R, Odou P, Gressier B, Luyckx M, Brunet C, Ballester L, Cazin M, Cazin JC. High-performance liquid chromatographic determination of naltrexone in plasma of hemodialysis patients. Biomed Chromatogr 2000;14:151-5. [DOI: 10.1002/1099-0801(200005)14:3<151::aid-bmc941>3.0.co;2-e] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
176 Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015;2015:295891. [PMID: 25861254 DOI: 10.1155/2015/295891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
177 Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
178 Mettang T. Chronic Kidney Disease-Associated Pruritus. In: Misery L, Ständer S, editors. Pruritus. London: Springer; 2010. pp. 166-75. [DOI: 10.1007/978-1-84882-322-8_27] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
179 Nichols AA. Cholestasis of Pregnancy: A Review of the Evidence. The Journal of Perinatal & Neonatal Nursing 2005;19:217-25. [DOI: 10.1097/00005237-200507000-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
180 Ward SK, Roenigk HH, Gordon KB. DERMATOLOGIC MANIFESTATIONS OF GASTROINTESTINAL DISORDERS. Gastroenterology Clinics of North America 1998;27:615-36. [DOI: 10.1016/s0889-8553(05)70023-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
181 Bergasa NV. Pruritus in chronic liver disease: mechanisms and treatment. Curr Gastroenterol Rep 2004;6:10-6. [PMID: 14720448 DOI: 10.1007/s11894-004-0020-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
182 Saleh MM, Abdo KR. Intrahepatic cholestasis of pregnancy: review of the literature and evaluation of current evidence. J Womens Health (Larchmt) 2007;16:833-41. [PMID: 17678454 DOI: 10.1089/jwh.2007.0158] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
183 Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857-870. [PMID: 12656688 DOI: 10.1046/j.1365-2036.2003.01458.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
184 Mani AR, Rasool R, Montagnese S, Dehpour AR. Endogenous opioids and liver disease. Scandinavian Journal of Gastroenterology 2009;41:1-11. [DOI: 10.1080/00365520500287533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000;118:431-2. [PMID: 10648471 DOI: 10.1016/s0016-5085(00)70225-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
186 Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol 2011;165:5-17. [PMID: 21219293 DOI: 10.1111/j.1365-2133.2011.10217.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
187 Andoh T, Yageta Y, Takeshima H, Kuraishi Y. Intradermal Nociceptin Elicits Itch-Associated Responses Through Leukotriene B4 in Mice. Journal of Investigative Dermatology 2004;123:196-201. [DOI: 10.1111/j.0022-202x.2004.22704.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
188 Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas J Dermatol 1997;38:196-8. [PMID: 9431714 DOI: 10.1111/j.1440-0960.1997.tb01696.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
189 Oude Elferink RP, Kremer AE, Beuers U. Mediators of pruritus during cholestasis. Curr Opin Gastroenterol. 2011;27:289-293. [PMID: 21451412 DOI: 10.1097/mog.0b013e32834575e8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
190 Feramisco JD, Berger TG, Steinhoff M. Innovative management of pruritus. Dermatol Clin 2010;28:467-78. [PMID: 20510757 DOI: 10.1016/j.det.2010.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
191 Shimizu K, Andoh T, Yoshihisa Y, Shimizu T. Histamine Released from Epidermal Keratinocytes Plays a Role in α-Melanocyte–Stimulating Hormone-Induced Itching in Mice. The American Journal of Pathology 2015;185:3003-10. [DOI: 10.1016/j.ajpath.2015.07.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
192 Saab S, Han S, Martin P. LIVER TRANSPLANTATION. Clinics in Liver Disease 2000;4:513-32. [DOI: 10.1016/s1089-3261(05)70124-0] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
193 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
194 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
195 Levy C, Lindor KD. Drug-induced cholestasis. Clinics in Liver Disease 2003;7:311-30. [DOI: 10.1016/s1089-3261(03)00032-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
196 Lisboa LF, Asthana S, Kremer A, Swain M, Bagshaw SM, Gibney N, Karvellas CJ. Blood cytokine, chemokine and gene expression in cholestasis patients with intractable pruritis treated with a molecular adsorbent recirculating system: a case series. Can J Gastroenterol 2012;26:799-805. [PMID: 23166903 DOI: 10.1155/2012/623862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
197 Bates JJ, Foss JF, Murphy DB. Are Peripheral Opioid Antagonists the Solution to Opioid Side Effects?: . Anesthesia & Analgesia. [DOI: 10.1213/01.ane.0000090147.97636.77] [Cited by in Crossref: 41] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
198 Ghafourifar P, Dehpour AR, Akbarloo N. Inhibition by L-NA, a nitric oxide synthase inhibitor, of naloxone-precpitated withdrawal signs in a mouse model of cholestasis. Life Sciences 1997;60:PL265-70. [DOI: 10.1016/s0024-3205(97)00115-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
199 Bergasa NV. Treatment of the pruritus of cholestasis. Curr Treat Options Gastro 2004;7:501-8. [DOI: 10.1007/s11938-004-0009-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
200 Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis. 2003;7:879-900. [PMID: 14594135 DOI: 10.1016/s1089-3261(03)00105-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
201 Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol 2019;81:1371-8. [PMID: 31009666 DOI: 10.1016/j.jaad.2019.04.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
202 Lebovics E, Seif F, Kim D, Elhosseiny A, Dworkin BM, Casellas A, Clark S, Rosenthal WS. Pruritus in chronic hepatitis C: association with high serum bile acids, advanced pathology, and bile duct abnormalities. Dig Dis Sci. 1997;42:1094-1099. [PMID: 9149069 DOI: 10.1023/a:1018865809556] [Cited by in Crossref: 33] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
203 Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680-688. [PMID: 20462660 DOI: 10.1016/j.jaad.2009.08.052] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
204 Carrion AF, Rosen JD, Levy C. Understanding and Treating Pruritus in Primary Biliary Cholangitis. Clinics in Liver Disease 2018;22:517-32. [DOI: 10.1016/j.cld.2018.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
205 Cotes ME, Swerlick RA. Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus. Dermatol Ther 2013;26:120-34. [PMID: 23551369 DOI: 10.1111/dth.12026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
206 . Perhaps not everyone knows that. Annals of Oncology 1995;6:959-60. [DOI: 10.1093/oxfordjournals.annonc.a059087] [Reference Citation Analysis]
207 Jones E. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. Journal of Hepatology 2002;37:863-5. [DOI: 10.1016/s0168-8278(02)00347-1] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
208 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008;22:505-7. [PMID: 18478137 DOI: 10.1155/2008/969826] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
209 Andoh T, Takayama Y, Yamakoshi T, Lee JB, Sano A, Shimizu T, Kuraishi Y. Involvement of serine protease and proteinase-activated receptor 2 in dermatophyte-associated itch in mice. J Pharmacol Exp Ther 2012;343:91-6. [PMID: 22761302 DOI: 10.1124/jpet.112.195222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
210 Bigliardi-qi M, Gaveriaux-ruff C, Pfaltz K, Bady P, Baumann T, Rufli T, Kieffer BL, Bigliardi PL. Deletion of μ- and κ-Opioid Receptors in Mice Changes Epidermal Hypertrophy, Density of Peripheral Nerve Endings, and Itch Behavior. Journal of Investigative Dermatology 2007;127:1479-88. [DOI: 10.1038/sj.jid.5700661] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
211 Mayo MJ. Natural history of primary biliary cirrhosis. Clin Liver Dis. 2008;12:277-288. [PMID: 18456180 DOI: 10.1016/j.cld.2008.02.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
212 Mohi-ud-din R, Lewis JH. Drug- and chemical-induced cholestasis. Clin Liver Dis. 2004;8:95-132, vii. [PMID: 15062196 DOI: 10.1016/s1089-3261(03)00124-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
213 Ghaffari K, Savadkuhi ST, Honar H, Riazi K, Shafaroodi H, Moezi L, Ebrahimkhani MR, Tahmasebi MS, Dehpour AR. Obstructive cholestasis alters intestinal transit in mice: role of opioid system. Life Sci. 2004;76:397-406. [PMID: 15530502 DOI: 10.1016/j.lfs.2004.09.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
214 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
215 Jones E, Zylicz Z. Treatment of Pruritus Caused by Cholestasis with Opioid Antagonists. Journal of Palliative Medicine 2005;8:1290-4. [DOI: 10.1089/jpm.2005.8.1290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
216 Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46. [PMID: 22541702 DOI: 10.1016/j.cld.2012.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
217 Gholyaf M, Sheikh V, Yasrebifar F, Mohammadi Y, Mirjalili M, Mehrpooya M. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study. Int Urol Nephrol 2020;52:1155-65. [PMID: 32383050 DOI: 10.1007/s11255-020-02473-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
218 Nelson L, Vergnolle N, D'Mello C, Chapman K, Le T, Swain MG. Endogenous opioid-mediated antinociception in cholestatic mice is peripherally, not centrally, mediated. J Hepatol 2006;44:1141-9. [PMID: 16466825 DOI: 10.1016/j.jhep.2005.11.043] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
219 Stauber R, Krisper P, Zollner G, Iberer F, Beuers U, Trauner M. Extracorporeal Albumin Dialysis in a Patient with Primary Sclerosing Cholangitis: Effect on Pruritus and Bile Acid Profile. Int J Artif Organs 2004;27:342-4. [DOI: 10.1177/039139880402700411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
220 Bergasa NV, Mohajer B, Maisonneuve IM, Ho A, Maidment NT, Olive F, Gunduz M, Kreek MJ. Basal total opioid peptide release in the striatum of rats with cholestasis from bile duct resection: a study by the use of in vivo microdialysis. Life Sci 1997;61:1169-75. [PMID: 9315507 DOI: 10.1016/s0024-3205(97)00658-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
221 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
222 Bergasa NV. The pruritus of cholestasis. J Hepatol. 2005;43:1078-1088. [PMID: 16253381 DOI: 10.1016/j.jhep.2005.09.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]